Systematic review of the incidence and prevalence of genital warts

H Patel, M Wagner, P Singhal, S Kothari - BMC infectious diseases, 2013 - Springer
Abstract Background Anogenital warts (AGWs) are a common, highly infectious disease
caused by the human papillomavirus (HPV), whose high recurrence rates contribute to direct …

Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer

C Chelimo, TA Wouldes, LD Cameron, JM Elwood - Journal of Infection, 2013 - Elsevier
Genital HPV infection is associated with development of cervical cancer, cervical neoplasia,
anogenital warts, and other anogenital cancers. A number of reviews have primarily …

2019 IUSTI‐Europe guideline for the management of anogenital warts

R Gilson, D Nugent, RN Werner… - Journal of the …, 2020 - Wiley Online Library
This guideline is an update of the 2011 European Guideline for the Management of
Anogenital Warts. It is intended to support best practice in the care of patients with …

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo …

LL Villa, RLR Costa, CA Petta, RP Andrade… - The lancet …, 2005 - thelancet.com
Background A randomised double-blind placebo-controlled phase II study was done to
assess the efficacy of a prophylactic quadrivalent vaccine targeting the human …

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

EA Joura, SM Garland, J Paavonen, DG Ferris, G Perez… - Bmj, 2012 - bmj.com
Objectives To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on
the risk of developing subsequent disease after an excisional procedure for cervical …

[HTML][HTML] Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and …

Future I/II Study Group - The BMJ, 2010 - ncbi.nlm.nih.gov
Objectives To evaluate the prophylactic efficacy of the human papillomavirus (HPV)
quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial …

Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions

AR Giuliano, G Tortolero-Luna, E Ferrer, AN Burchell… - Vaccine, 2008 - Elsevier
Human papillomavirus (HPV) infection is commonly found in the genital tract of men and
women with or without any clinical lesion. The association of HPV DNA with several different …

2012 European guideline for the management of anogenital warts

CJN Lacey, SC Woodhall, A Wikstrom… - Journal of the …, 2013 - Wiley Online Library
Background Although new HPV vaccines have been developed and are in the process of
implementation, anogenital warts remain a very frequent problem in clinical practice …

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

LL Villa, KA Ault, AR Giuliano, RLR Costa, CA Petta… - Vaccine, 2006 - Elsevier
Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young
women (1106) were randomized to receive one of three formulations of a quadrivalent HPV …

Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review

S Hartwig, S Syrjänen, G Dominiak-Felden, M Brotons… - BMC cancer, 2012 - Springer
Background The role of human papillomavirus (HPV) in malignant and non-malignant
genital diseases in women is well known and the corresponding epidemiological burden …